ArticleMultiple sclerosis journal - experimental, translational and clinical
Baricitinib triggering a central nervous system inflammatory-demyelinating disease: A case report.
Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Janus kinase inhibitors (JAKis), such as baricitinib, target the Janus kinase/signal transducers and activators of transcription pathway to regulate proinflammatory cytokines and T-helper cell activity, thereby reducing inflammation. Despite their therapeutic benefits, inflammatory demyelinating diseases of the central nervous system (CNS) have been reported in association with JAKi treatment, most previously involving tofacitinib in patients with rheumatoid arthritis. We report the first case of a CNS inflammatory demyelinating disease that was possibly exacerbated by baricitinib, underscoring the need for heightened clinical vigilance and close monitoring of patients receiving JAKi therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.